February 19, 2026
“… …” https://finance.yahoo.com/news/2-undervalued-ai-stocks-buy-093200646.html Side note: When I share these articles that doesn’t mean I agree or disagree with with these people are saying. My opinion is neutral unless I say otherwise.
January 26, 2026
“…Acumen Pharmaceuticals (ABOS)… With a major catalyst ahead and ABOS shares trading at $1.98, Stifel’s 5-star analyst Paul Matteis thinks now is the right time to make a move… To this end, Matteis rates ABOS a Buy, and his $10 price… Continue Reading…
January 22, 2026
“…Riot Platforms bounced back by 16.11 percent on Friday to finish at $19.24 apiece after bagging a data center lease and services agreement with Advanced Micro Devices Inc. (AMD), which could potentially generate the former up to $1 billion in… Continue Reading…
January 22, 2026
“…Shares of the iShares Semiconductor ETF (NASDAQ: SOXX) were soaring last year, reflecting the continuing AI boom… According to S&P Global Market Intelligence, the ETF finished the year up 40%… iShares’ top three holdings are now Micron (Nasdaq: MU), Nvidia, and AMD, with each one making more than… Continue Reading…
March 20, 2025
https://www.cnbc.com/2025/03/20/us-households-are-more-invested-in-stocks-than-ever-and-its-distorting-market-valuation-says-jpmorgan.html This article is behind a paywall. From the looks of the title it seems as though some people are mad that the general public is investing in stocks. “Distorting market valuation?” The market value is what people are willing… Continue Reading…
October 1, 2024
“…UiPath: 212% implied upside… Going forward, Wall Street expects UiPath to grow sales at 10% annually through fiscal 2026 (ends April 2026). That estimate leaves room for upside because the RPA market is forecasted to grow at 40% annually through… Continue Reading…
September 17, 2024
I’ve been busy watching the the meme stock plays. During this time I came across some pretty useful information. I’ll keep people updated by sharing links, etc. Click here to watch video.
September 4, 2024
“…COMPASS Pathways (CMPS)… Morgan Stanley analyst Vikram Purohit, who covers the stock, sees CMPS as presenting a compelling risk-reward opportunity. He highlights the company’s leading clinical program… To this end, Purohit rates CMPS shares an Overweight (i.e. Buy), and his $23 price… Continue Reading…
August 12, 2024
“CervoMed (CRVO) The first Morgan Stanley pick we’ll look at is CervoMed, a clinical-stage medical research firm specializing in neurodegenerative diseases and conditions… Overall, the analyst expects positive clinical results and rates CRVO an Overweight (i.e., Buy). His $35 price… Continue Reading…
Recent Comments